Share this article and save a life!
81% cancer detection with AI mammography. Are we finally winning?
A groundbreaking Lancet trial just dropped results that should make every healthcare executive pay attention.
200,000 mammograms. 10+ countries. One stunning outcome:
AI-assisted screening detected 81% of cancers at screening, compared to 74% with standard double-reading. That’s not a marginal improvement, that’s transformational.
But here’s what really caught my eye:
📊 27% fewer aggressive cancers missed
📊 21% fewer large tumors developing
📊 12% reduction in interval cancers (those sneaky ones found between screenings)
📊 44% reduction in radiologist workload
Google’s NHS study added another bombshell: their AI caught 25% of interval cancers that human radiologists missed entirely.
Think about what this means for your imaging centers and screening programs.
We’re not just finding more cancers. We’re finding them smaller, earlier, when they’re actually treatable. We’re catching the aggressive ones that kill. And we’re doing it while our radiologists read 32% faster.
With radiologist shortages crushing departments nationwide, this isn’t just innovation, it’s survival.
The question isn’t whether to adopt AI mammography anymore.
The question is: can you afford not to?
Every day we delay implementation is another day of preventable late-stage diagnoses. Another day of burned-out radiologists drowning in reads. Another day we’re failing the 1 in 8 women who will face breast cancer.
Your competitors are already moving on this. Insurance is starting to cover it. Patients will demand it.
What’s your timeline?
♻️ Repost if early cancer detection should be a healthcare priority
👉 Follow me, Jonathan Govette, for daily, real-time updates on healthcare technology and business news. LinkedIn Profile: https://www.linkedin.com/in/jonathangovette/
Share this article and save a life!
Author:
CEO/Co-Founder @ Oatmeal Health | AI Lung Cancer Screening | Almost Became a Doctor | Engineer | Follow to Share What I’ve Learned Along the Way
I help patients get the care they need earlier, preventing late-stage cancer.
That’s been the throughline across three companies and almost 20 years in healthcare. At ReferralMD, we fixed broken referral networks so patients didn’t fall through the cracks. At Oatmeal Health, it’s lung cancer: building the diagnostic and screening infrastructure so the 85% of cases caught too late get caught early instead.
Today as CEO of Oatmeal Health, I lead a team embedding AI into radiology workflows to turn routine lung CT scans into reimbursable cancer risk assessments. We partner with FQHCs to reach underserved communities, and with health systems and payers to make early detection economically sustainable. Think HeartFlow or Cleerly, but for lungs.
Between companies, I advised at Techstars and Plug and Play, mentoring founders building in digital health. That experience shaped how I think about what separates companies that ship from companies that stall: distribution, reimbursement, and clinical trust, not just technology.
I’m a CancerX alumnus, a 3x healthcare founder, and someone who believes the biggest problems in cancer aren’t scientific. They’re operational.
We’re hiring mission-driven builders at Oatmeal Health. If you want to work on something that matters, reach out.
When I’m not working, I’m traveling, mentoring, and keeping up with one very energetic husky. 🐾
Substack – The Oatmeal Bite:
Millions of patients get less care because of who they are, where they live, or how they look. I’m fighting to change that. CEO @OatmealHealth, a startup built for the underserved. The Oatmeal Bite: intel for clinicians, investors, and advocates.
Jonathan Govette
CEO of Oatmeal Health
Substack:
https://oatmealhealthjonathangovette.substack.com/
